









Markets
/
Stocks
/
nasdaq-mirm
/

Mirum Pharmaceuticals Inc

MIRM

74.380USD

-0.940-1.25%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

3.72BMarket Cap

LossP/E TTM



Mirum Pharmaceuticals Inc

74.380

-0.940-1.25%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

13 / 175

Overall Ranking

85 / 4720

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 10 analysts

Buy

Current Rating

79.889

Target Price

+6.07%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development and commercialization of therapies for debilitating rare and orphan diseases. It has three medicines: LIVMARLI (maralixibat) oral solution (Livmarli), Cholbam (cholic acid) capsules, and Chenodal (chenodiol) tablets. Livmarli is an orally administered, minimally-absorbed ileal bile acid transporter (IBAT) inhibitor (IBATi) that is used for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) in the United States and various other countries and for cholestatic pruritus in patient with progressive familial intrahepatic cholestasis (PFIC) in the United States. Cholbam is used for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders. It is also advancing its product candidate, volixibat, for the treatment of adult patients with cholestatic liver diseases.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 337.16% year-on-year.

Undervalued

The company’s latest PE is -61.63, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 58.36M shares, decreasing 7.30% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 2.56M shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 0.72.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 8.17, which is higher than the Pharmaceuticals industry's average of 7.84. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 127.78M, representing a year-over-year increase of 64.09%, while its net profit experienced a year-over-year increase of 76.21%.

Score

Industry at a Glance

Previous score

8.17

Change



Financials

8.09

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

5.15

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.63

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 1.20, which is lower than the Pharmaceuticals industry's average of 2.06. Its current P/E ratio is -62.41, which is -88.99% below the recent high of -6.87 and 68.22% above the recent low of -19.84.

Score

Industry at a Glance

Previous score

1.20

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 13/175

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

The company’s current earnings forecast score is 8.80, which is higher than the Pharmaceuticals industry's average of 7.78. The average price target for Mirum Pharmaceuticals Inc is 81.00, with a high of 89.00 and a low of 66.00.

Score

Industry at a Glance

Previous score

8.80

Change

Support & Resistance

No Data

Analyst Rating

Based on 10 analysts

Buy

Current Rating

79.889

Target Price

+6.07%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

179

Total

Median

Average

Company name

Ratings

Analysts

Mirum Pharmaceuticals Inc

MIRM

Biogen Inc

BIIB

Amgen Inc

AMGN

Vertex Pharmaceuticals Inc

VRTX

Alnylam Pharmaceuticals Inc

ALNY

Eli Lilly and Co

LLY

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 9.25, which is higher than the Pharmaceuticals industry's average of 6.84. Sideways: Currently, the stock price is trading between the resistance level at 80.25 and the support level at 68.25, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.25

Change

-0.38

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(4)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-1.724

Neutral

RSI(14)

60.308

Neutral

STOCH(KDJ)(9,3,3)

37.133

Neutral

ATR(14)

2.469

High Vlolatility

CCI(14)

-50.251

Neutral

Williams %R

59.679

Sell

TRIX(12,20)

0.674

Sell

StochRSI(14)

32.409

Sell

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

74.164

Buy

MA10

75.108

Sell

MA20

74.593

Sell

MA50

63.985

Buy

MA100

55.438

Buy

MA200

50.215

Buy

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 10.00, which is higher than the Pharmaceuticals industry's average of 6.26. The latest institutional shareholding proportion is 116.21%, representing a quarter-over-quarter decrease of 0.15%. The largest institutional shareholder is The Vanguard, holding a total of 2.56M shares, representing 5.09% of shares outstanding, with 1.05% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Frazier Life Sciences Management, L.P.

6.80M

+82.21%

Janus Henderson Investors

5.08M

+1.66%

BlackRock Institutional Trust Company, N.A.

3.02M

-2.64%

BVF Partners L.P.

2.80M

Eventide Asset Management, LLC

2.53M

-3.07%

The Vanguard Group, Inc.

Star Investors

2.53M

+4.77%

Novo Holdings A/S

1.50M

Citadel Advisors LLC

1.45M

-4.31%

T. Rowe Price Associates, Inc.

Star Investors

1.38M

-0.60%

State Street Global Advisors (US)

1.49M

+8.17%

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 5.43, which is higher than the Pharmaceuticals industry's average of 4.07. The company's beta value is 0.82. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.